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CObjective: Specific methodological challenges are often encountered
during cancer-related economic evaluations. The objective of this
study was to provide specific guidance to analysts on the methods for
the conduct of high-quality economic evaluations in oncology by build-
ing on the Canadian Agency for Drugs and Technologies in Health
Guidelines for the Economic Evaluation of Health Technologies (third
edition). Methods: Fifteen oncologists, health economists, health
services researchers, and decision makers from across Canada iden-
tified sections in Canadian Agency for Drugs and Technologies in
Health guidelines that would benefit from oncology-specific guid-
ance. Fifteen sections of the guidelines were reviewed to determine
whether 1) Canadian Agency for Drugs and Technologies in Health
guidelines were sufficient for the conduct of oncology economic
evaluations without further guidance specific for oncology products
or 2) additional guidance was necessary. A scoping review was con-
ducted by using a comprehensive and replicable search to identify O
Cent
al So
doi:10.1016/j.jval.2011.12.006elevant literature to inform recommendations. Recommendations
ere reviewed by representatives of academia, government, and the
harmaceutical industry in an iterative and formal review of the
ecommendations. Results: Major adaptations for guidance related
o time horizon, effectiveness, modeling, costs, and resources were
equired. Recommendations around the use of final outcomes over
ntermediate outcomes to calculate quality-adjusted life-years and
ife-years gained, the type of evidence, the source of evidence, and
he use of time horizon and modeling were made. Conclusions: This
rticle summarizes key recommendations for the conduct of economic
valuations in oncology and describesmethods required to ensure that
conomic assessments in oncology are conducted in a standardized
anner.
eywords: Canada, guidelines, health economic evaluations, oncology.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Cancer is responsible for a large burden of illness. The growing
burden of cancer has stimulated research into the underlying
causes of and biological changes associated with the malignant
process. Increasing knowledge about the biology of cancer at
the molecular level has led to the discovery of new therapeutic
interventions. Many of these new interventions are very expen-
sive and confer modest clinical benefits. Thus, explicit consid-
eration of the tradeoffs between cost and benefits has a partic-
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Published by Elsevier Inc.ular and growing salience in cancer. Consequently, there are
increasing demands for health economic evaluations in the on-
cology setting.
In Canada, national guidance on the conduct of economic eval-
uations has been available through theCanadianAgency for Drugs
and Technologies in Health (CADTH) since 1994 [1–3]. Despite the
available guidelines, specific methodological challenges are often
encountered during cancer-related health economic evaluations.
Some of these challenges include selection of outcomes, methods
to estimate survival gain, time horizon, and which toxicities to
include. These variables introduce heterogeneity and uncertainty
re, Scientist, Sunnybrook Health Sciences Centre, 2075 Bayview
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guidance does not allow for a consistent or standardized approach
across economic evaluations of oncology products. CADTH re-
cently published an addendum to its existing guidelines for the
conduct of economic evaluations for oncology products [4]. That
document provides clear and practical guidance on the methods
for the conduct of credible economic analyses in the oncology
setting. Standardization of evaluative methods is intended to en-
courage consistent approaches to the evaluation and reimburse-
ment decisions.
The question ofwhether cancer requires a distinct set of guide-
lines for economic evaluations andwhether they are conducted in
a consistent manner is of interest [5,6]. In terms of rationale for
thiswork, this oncology guidance documentwas initiated because
of the following reasons: 1) within Canada there is a unique and
evolving reimbursement environment within which cancer drugs
often have a separate evaluation and funding process; 2) the re-
ported observed heterogeneity and quality of analyses in oncology
submissions to decision-making bodies underscored the need for
oncology-specific guidance; and 3) the heavy burden of cancer
(both economic and human) gives cancer a high priority for
heightened considerations around resource allocation, including
the time of researchers to develop guidance documents. A key
enabler to this initiative was a group of collaborative researchers
in Canada compelled by this topic and willing to collaborate in
guideline development. The work to produce an oncology-specific
guidance document on economic analysis was undertaken as a
collaborative effort between members from the National Cancer
Institute of Canada Clinical Trials Group, Committee on Economic
Analysis (formerly theWorking Group on Economic Analysis), and
CADTH. Fifteen experts in oncology, health economics, health ser-
vices research, and policy development were involved, designated
the Oncology Guidelines Working Group (OGWG). This oncology-
specific guideline is considered a companion document to CADTH
guideline document. Irrespective of arguments in favor of or
against oncology-specific guidance, we provide here concepts and
methods for the conduct of these evaluations. Decisionmakers are
faced with the considerable challenge of making reimbursement
decisions for new drugs and therapies that are very expensive and
confer modest clinical benefits. Tools and methods to ensure that
assessments are conducted in a standardized manner are re-
quired.
Economic evaluations conducted with more consistency and
transparency are intended to help those who make recommen-
dations on whether to approve funding for new cancer thera-
pies and those who conduct economic evaluations. Indeed, re-
cent publications have highlighted the need for journals
publishing economic evaluations to provide specific guidance
or conducting and reporting economic evaluations in the area of
ncology [5,7].
The overarching goal of this work was to provide specific guid-
nce to analysts on the methods for the conduct of high-quality
conomic evaluations in oncology using CADTHGuidelines for the
conomic Evaluation of Health Technologies (third edition) [1] as a
frame of reference. This oncology-specific document focuses on
guidance for the conduct of technology assessment specific to
cancer; it also provides guidance on what may be considered ac-
ceptable when gold standard methods cannot be used for justifi-
able reasons.
Methods
Identification
The OGWG was tasked with evaluating how comprehensive the
CADTH guidelines were, as applied to economic evaluations of
oncology interventions. The current CADTH guideline consists of15 sections, and each sectionwas reviewed by all OGWGmembers
in a facilitated workshop. During the workshop, OGWG members
identified the chapters of CADTH Guidelines for the Economic
Evaluation of Health Technologies (third edition) that could bene-
fit from oncology-specific guidance. By a majority consensus rul-
ing presided over by the facilitator and cochairs, OGWG identified
the sections of the CADTH guidelines that could use additional
oncology-specific guidance. The OGWG classified the sections as
requiring major (extensive), minor (clarifications, descriptions,
and further refinement of original definitions), and no adapta-
tions.
Literature search
Guideline sections requiring additional guidance as per the above
consensus methodology were divided up among groups of OGWG
members. Because of the breadth of the topics being covered, ar-
ticles could not be selected according to the systematic application
of predefined selection criteria, as is typically done in conduct of a
clinical systematic review. Instead, the method used to identify
research can be thought of as a scoping review, which uses a rep-
licable search strategy to identify literature in a transparent and
rigorous fashion [8]. Formal search strategies were prepared and
run by CADTH Information Specialists with input from OGWG
members. Literature searches were conducted for the following
variables: value of outcomes, modeling, adverse events, time ho-
rizons, and surrogate outcomes. Databases searched included the
following:
1. EBM Reviews—Cochrane Central Register of Controlled Trials
(1st Quarter 2008);
2. EBM Reviews—NHS Economic Evaluation Database (1st Quarter
2008);
3. Econlit (1969 to January 2008);
4. EMBASE (1996 to 2008 Week 05);
5. Ovid MEDLINE(R) InProcess and Other NonIndexed Citations;
6. Ovid MEDLINE(R) (1950 to Present).
Search criteria included Medical Subject Headings (exploded)
for neoplasms, cancer, tumor (tumour), carcinoma, metastases,
malignancies, and oncology linked to Medical Subject Heading of
economics/cost analysis (exploded); English language; and then
merged with one of the variables of interest listed above. The
searches and corresponding articleswere distributed to theOGWG
members. OGWG members leading a guideline section also con-
ducted supplemental searches and searches of the gray literature.
Gray literature was identified by searching theWeb sites of health
technology assessment and related agencies, professional associ-
ations, and other specialized databases. Google and other Internet
search engines were used to search for additional information.
Articles identified through the search strategies were reviewed by
the leads for the assigned guideline sections of the document.
Recommendations
A hierarchical approach to evidence was used in the construction
of this guideline document. The highest quality evidence was rec-
ommended for use in the conduct of economic evaluations for
oncology interventions in accordance with CADTH guidelines.
When the highest level of evidence was unavailable (e.g., whether
a randomized clinical trial was conducted), the document pro-
vided guidance on exceptions and alternatives that may be con-
sidered when conducting economic evaluations under such cir-
cumstances. Iterative reviews of the work (29 cycles) were
conducted by the academic community, Canadian pharmaceuti-
cal industry, government, CADTH, and OGWG members.
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In this article, we focus on aspects of economic evaluations of
oncology interventions for which specific guidance for the general
CADTH statements requiring major adaptations was developed.
Identification and search
Of the 15 sections in CADTHguidelines, OGWGmembers indicated
that no oncology-specific guidance was needed for the following
chapters: Study Question, Type of Evaluation, Valuing Outcomes,
Reporting, Generalizability, Equity, andDiscounting. Itwas recom-
mended that four guideline sections required guidance in the form
ofminor adaptations (Target Population, Comparator, Perspective,
Variability/Uncertainty) and four guideline sections required ma-
jor adaptations (Effectiveness, Time Horizon, Modeling, Resources
and Costs) (Table 1). What follows are specific guidance state-
ments regarding those sections that OGWGmembers felt required
the most clarification for economic evaluations of oncology prod-
ucts. The full technical report provides complete details for all
guidance recommendations [4].
Effectiveness: general statements
In oncology, the clinical outcomes of importance depend on the
therapeutic intent, which may be curative or palliative. The goal
for the curative group, which includes adjuvant therapy, is to cure
the disease by decreasing cancer relapse and cancer mortality,
extending survival [9]. The goals in treating patients with pallia-
tive intent are to improve the symptoms associated with terminal
cancer, to improve the quality of life, and to extend survival where
possible. In curative or adjuvant clinical studies, overall survival
(OS) has been the gold standard and preferred primary end point.
OS is a clinical outcome that directlymeasures substantial clinical
benefit to cancer patients. As a result, OS is the most commonly
used objective clinical parameter for determining the benefit of an
anticancer intervention.
Nevertheless, the impact of toxicity on the patient is not cap-
tured when OS is used alone. As a result, for economic analyses,
treatment and disease burden measures that capture health-re-
lated quality of life, such as the quality-adjusted life-year (QALY),
are considered to be a more relevant end point because they com-
bine OS and the impact of the toxicity and the symptoms of the
Table 1 – Oncologic adaptation of general guidelines for
the economic evaluation of health technologies.
Recommendations
added to general
guideline statement
No
adaptation
Minor
adaptation
Major
adaptation
Study question X
Type of evaluation X
Target population X
Comparator X
Perspective X
Effectiveness X
Time horizon X
Modeling X
Valuing outcomes X
Resource use and costs X
Discounting X
Variability/uncertainty X
Generalizability X
Reporting X
Equity Xdisease itself on quality of life into a single measure.The oncology guidelines recommend that OS (translated into
life-years gained [LYG]) should be the key outcomewhen there are
no anticipated differences in health-related quality of life when
different curative interventions are compared. The lack of differ-
ence in toxicitymust be justified by available clinical data. The use
of OS alone as a final outcomemeasuremay be justified if there are
no concerns about disutility between therapies [10].
Effectiveness: surrogate outcomes in oncology
The CADTH guidelines recommend that final outcomes, such as
deaths prevented and serious morbidity avoided, which directly
translate into LYG, healthy-year equivalents, or QALYs, are pre-
ferred outcomes for health economic evaluations. In oncology,
however, this may be problematic because analysts might choose
to use an intermediate outcome (e.g., progression-free survival)
versus a final outcome because of data availability.
The use of surrogate outcomes in economic analyses for oncol-
ogy agents has received increasing attention of late [11–15]. The
appropriate methods to establish the relationship between a sur-
rogate outcome and a final outcome include single-trial analysis,
meta-analysis, and hybrid approaches [16,17]. In general, a surro-
gate end point can be used as a valid outcomemeasurewhen there
is a plausible biological rationale and empirical data showing that
it is a reliable predictor of OS. Recent literature discusses benefits
and limitations of surrogate outcomes in the field of oncology
[18–20]. Two tumor types in which the linkage between surrogate
markers and final outcomes has been established are colorectal
cancer [21–23] and breast cancer [24,25], specifically a correlation
between progression-free survival and OS. The fact that this cor-
relation has been established in breast and colorectal cancers does
not imply that a predictive correlation exists for all tumor types.
The relationship between a proposed surrogate measure and
final outcomes will have an impact on the uncertainty of the anal-
yses, which needs to be explicitly recognized by the analyst. The
analyst will need to consider the certainty of the comparative ef-
fect of treatment and of the extrapolation of this effect. If little is
known about the extrapolative relationship between the proposed
surrogate measure and the final outcome, a scenario analysis, or
weighted scenario analysis that examines a plausible spectrum of
predicted events, including the possibility of a negatively corre-
lated relationship, needs to be considered. The oncology guide-
lines recommend that extrapolation from surrogate outcomes to a
QALY or LYGmust be accompanied by an appropriate justification
based on the best available evidence. A surrogate outcome should
be used as the primary outcomemeasure onlywhen there is either
clear evidence of correlation with the final outcome or a compel-
ling reason why survival cannot be used.
Effectiveness: quality of evidence
It should be recognized that nonrandomized, noncomparative tri-
als in oncology have specific problems (e.g., potential for bias, lack
of comparability) [26]. Any use of alternative sources of data and
study designs must be justified and referenced. The use of lower
quality efficacy and effectiveness evidence in economic assess-
ments increases the level of uncertainty about the results [27] and
should be accompanied by extensive sensitivity analyses. Evalua-
tions that use this lower quality evidence must acknowledge the
limitations of the available evidence.
When the results from well-conducted randomized controlled
trials (RCTs) are not available, analysts must consider the quality
of the available evidence andwhether or not the results have been
peer reviewed and/or are publicly available. Consequently, data
from non-RCT study designs may need to be considered, particu-
larly when randomized trials cannot be conducted for ethical or
other well-justified reasons. In these cases, data that are obtained
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economic evaluation.
These guidance recommendations refer specifically to evi-
dence in support of the primary outcome (efficacy/effective-
ness) of a new intervention. High-quality RCTs, however, may
not be the preferred or even appropriate data source for re-
source utilization patterns. Here, administrative databases of
patient and disease cohorts may be more relevant for data in-
puts on resource utilization or current practice patterns (e.g., to
describe a “standard care” arm).
Time horizon and modeling
The concepts of time horizon and modeling are related and pre-
sented together. To conduct an economic evaluation with the pre-
ferred outcome of LYG or QALYs, it is necessary to select a time
horizon. The general CADTH guidelines recommend that the
time horizon should match the natural course of the disease. A
lifetime horizon is preferred for an oncology economic evaluation,
and this will usually necessitate extrapolation beyond the data
available from a clinical trial, particularly for adjuvant trials in
which mature results may not be available for many years. Even
for palliative therapies, it is still a common occurrence to see
short-term results reported because of the demand for new treat-
ments. In both settings, extrapolation may also be needed to deal
with results limited to surrogate end points. Appropriatemodeling
techniques for each treatment type are needed and are described
in the general CADTH guidelines.
The duration of the effect or how long the effects of the inter-
vention are sustained plays a role in determining the time horizon
and how to extrapolate results. All survival curves eventually con-
verge; the challenge is to determinewhen thatwill occur. Truncating
an analysis at the end of the study may introduce bias in favor of
survivorship (if survival curves eventually cross) or may prevent the
appreciation of long-term benefits and costs.
When it is necessary to extrapolate beyond observed clinical
study data to populate a lifetime horizon model, it is recom-
mended that analysts consider the following scenarios to examine
the potential range of duration of benefit:
1. Scenario 1: Decrease in the treatment effect after the end of the clinical
study until the survival curves converge.This option is recommended
for the base case in an economic evaluation. The value of the
decrease and the duration of the decrease must be justified.
2. Scenario 2: Immediate loss of treatment effect or converging sur-
vival curves after the end of the clinical study. This is the most
conservative option. This option may not be clinically likely,
because the clinical effect of an outcome (final or surrogate)
would have to stop immediately at the end of a trial; however, it
mayservewell asasensitivityanalysisparameter. If chosenas the
base case, the clinical relevance must be justified.
3. Scenario 3: Maintain the clinical study treatment effect based on the
study effect until the survival curves converge. This is the least con-
servative option of the three listed for an economic analysis and
may not be clinically likely, because the clinical effect of a sur-
rogate outcome is unlikely to parallel precisely the final out-
come. Again, however, it may be considered for a sensitivity
analysis. If chosen as the base case, the clinical relevance of this
scenario must be justified (Fig. 1).
An important element of extrapolation techniques, particular
to oncology, is the selection of the best quantitative estimate of the
relevant parameter. Oncology trials frequently utilize the median
to define primary and secondary outcomes. For economic evalua-
tions, however, the arithmetic mean value is the preferred statis-
tical measure for both costs and consequences (outcomes) be-
cause it is the appropriate basis to create population-based policy.
The use of raw clinical data is the preferred method of determin-ing the mean. In cases where individual patient data are unavail-
able or incomplete, other methods (e.g., extrapolation and digiti-
zation) may be used.
Issues related to modeling in cancer are primarily due to the
high prevalence of censored data, skewed distributions of data,
and attrition in cancer studies. OGWG members thought that
other issues related to modeling oncology products in economic
evaluation including choice and structure ofmodels and valuation
of disease parameters (other than surrogates and extrapolation)
did not have any oncology-specific guidance, although some
might require attention in the future.
Resources and costs
CADTH guidelines provide guidance about the appropriate re-
sources on the basis of the perspective of the assessment. In on-
cology, it is recommended that the analyst use “real-world” utili-
zation and evidence-based treatment guidelines (e.g., Cancer Care
Ontario’s Program in Evidence-Based Care) to gather information
about resource utilization of items such as chemotherapy admin-
istration, personnel, drug preparation time, premedication drug
costs, and adverse event-related resources.
The inclusion of utilization data based on trials, protocols, and
guidelines may not represent real-world utilization. Real-world
utilization data can be obtained from several sources including
claims data, hospital admissions data, review of medical records,
and electronic health registry data. Resource utilization and pa-
tient epidemiology data can be obtained from unpublished
sources. Examples of clinical practice information include the fol-
lowing: administrative data sets (e.g., annual survival rates), med-
ical records (e.g., proportion of patients receiving a transfusion),
and patient registries (e.g., adverse event rates).
Discussion and Conclusion
Like other country-specific guidelines (e.g., United Kingdom, Scotland,
andAustralia), CADTHguidelines act as a foundational resource for an-
alystswhoareundertakinghealtheconomicevaluationsof therapeutic
productswhen the objective is “to assist the ‘doers’ of economic evalu-
ations (i.e., analysts) to produce credible and standardized economic
information that is relevant and useful to decisionmakers in Canada’s
publicly funded health care system” [1].
These oncology-specific guidelines were developed to ensure
that health technology evaluations of new oncology products in
Canada are conducted consistently and to address the need for
greater standardization in the analytic methods used in cancer-
related health technology evaluations [28].
The concept of disease-specific economic guidance is not
unique. In 1994, the OMERACT Economics Working Group (1994)
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Fig. 1 – Survival curve demonstrating potential strategies of
extrapolating survival data.
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nomic evaluations. This initiative was initially prompted by the
introduction of expensive biologics into the treatment armamen-
tarium for rheumatoid arthritis and a changing reimbursement
environment [29]. A more recent example of adaptations of guid-
ance is from the National Institute for Health and Clinical Excel-
lence with respect to changes in the valuation of benefit (health
preference and QALYs) in technologies that extend life for small
populations (where some of the targeted populationsmay include
oncology) [30]. Therefore, it is not implausible that disease-specific
uidelines could be developed in other therapeutic areas, such as
ncology, where general economic guidelines are very broad.
This oncology-specific guidance document may be limited in
that it builds on existing guidance statements. Consequently, this
document does not discuss recommendations around valuing
outcomes (rated as requiring no adaptation), equity (rated as re-
quiring no adaptation), or acceptable thresholds. The oncology
guidelines are considered an addendum to the general guidance
provided by the CADTH economic guidelines [1]. As an addendum
document, these recommendations are meant to build on the ex-
isting guideline statements. Because it is meant to build on exist-
ing statements, there is no guidance on health preference despite
it being an important outcome for economic evaluations and may
play a key role in oncology economic evaluations. For example,
complications or adverse events related to medication may result
in decrements in health preference value, which would likely af-
fect the incremental cost–utility ratio. There are also issues re-
lated to changes in preference in those at end of life. An adaptation
was not considered for this oncology guideline, because the gen-
eral CADTH guidelines do not recommend a specific health pref-
erence instrument for economic evaluations. This is in contrast to
National Institute for Health and Clinical Excellence, which favors
the EuroQol EQ-5D questionnaire [31]. At this time, analysts are
therefore free to use direct (e.g., standard gamble, time trade-
off) or indirect measures (e.g., Health Utilities Index Mark 3 and
EQ-5D questionnaire) for health preference determination in
Canada. Analysts are encouraged to continue to explore rela-
tionships between generic and disease-specific quality-of-life
instruments and patient-weighted utility instruments for on-
cology products.
Equity or “fairness” in the allocation of resources, treatments,
or outcomes among individuals or groups is a challenging issue,
particularly for rare conditions [32]. This document did not discuss
the equity issue. Nevertheless, if the same effectiveness criteria as
with other common diseases are applied, it is likely that treat-
ments of uncommon cancers will be associated with higher incre-
mental cost-effectiveness ratios than will treatments of other dis-
eases considered for reimbursement.
This document does not provide guidance for decision makers
in terms of incremental cost-effectiveness thresholds or how to
make decisions on rare diseases. Adherence to the recommenda-
tions in this document, however, will improve the quality of on-
cology economic evaluations. The use of these oncology guide-
lines is intended to promote a greater degree of uniformity among
economic evaluations, facilitating comparability and reducing re-
viewer subjectivity, as well as encouraging dialogue between an-
alysts, decision makers, and other stakeholders.
Other limitations include the fact that OGWGmembership did
not include pharmaceutical manufacturers on the core commit-
tee, which consisted of oncologists, health economists, health ser-
vices researchers, and policy developers. OGWG members have
acted in the capacity of analyst or reviewer for economic evalua-
tions. Although not in the OGWG, an iterative peer review of the
guidelines was conducted with manufacturers, academics, and
decision makers during the development of the guidelines.Finally, these guidelineswere developed and are applicable to a
Canadian audience where there is a separate decision-making
process for oncology products. Motivation for this guideline work
was based on the fact that jurisdictional decision makers in the
country were making heterogeneous decisions about oncology
products [28]. There was impetus to build a central agency (excep-
tion is the province of Quebec) for the review of clinical and eco-
nomic outcomes for oncology products, where standardization of
process and content was deliberated. The pan-Canadian Oncology
Drug Review was established “to assess the clinical evidence and
cost-effectiveness of new cancer drugs and to use this information
to make recommendations to the provinces and territories to
guide their drug funding decisions” [33,34]. Although this guide-
line has been developed with a Canadian focus, it may provide
valuable information for discussion in other health jurisdictions
and research environments.
In summary, this document represents the first phase in the
evolution of economic guidelines for oncology products. This doc-
ument will be updated, as more evidence on economic evaluation
methods becomes available and as economic evaluations of on-
cology products mature. We encourage researchers and analysts
to improve the methods that are used to conduct economic eval-
uations of oncology products and engage in ongoing dialoguewith
decision makers and other stakeholders.
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